DLC1 anticorps (C-Term)
Aperçu rapide pour DLC1 anticorps (C-Term) (ABIN630519)
Antigène
Voir toutes DLC1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Specificité
- DLC1 antibody was raised against the C terminal of DLC1
-
Purification
- Affinity purified
-
Immunogène
- DLC1 antibody was raised using the C terminal of DLC1 corresponding to a region with amino acids NLAVCLAPSLFHLNTLKRENSSPRVMQRKQSLGKPDQKDLNENLAATQGL
-
-
-
-
Indications d'application
-
WB: 0.5 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
DLC1 Blocking Peptide, (ABIN5613215), is also available for use as a blocking control in assays to test for specificity of this DLC1 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of DLC1 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- DLC1 (Deleted in Liver Cancer 1 (DLC1))
-
Autre désignation
- DLC1
-
Sujet
- This gene is deleted in the primary tumor of hepatocellular carcinoma. It maps to 8p22-p21.3, a region frequently deleted in solid tumors. It is suggested that this gene is a candidate tumor suppressor gene for human liver cancer, as well as for prostate, lung, colorectal, and breast cancers. DLC1 functions as a GTPase-activating protein specific for Rho and an activator of PLCD1 in vivo and induces morphological changes and detachment through cytoskeletal reorganization.
-
Poids moléculaire
- 52 kDa (MW of target protein)
-
Pathways
- Tube Formation, Positive Regulation of Endopeptidase Activity
Antigène
-